Introduction: Charting the landscape of cancer survivors' health‐related outcomes and care

Rowland, Julia H.; Crammer, Corinne; Stefanek, Michael

doi:10.1002/cncr.24579

Cited by 20 publications

(20 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Each year in the United States, approximately 21,200 women are diagnosed with OvCa (2200<45 years of age), and 14,300 die from the disease (470<45 years of age) (Pollack et al, 2009). The standard therapy for advanced epithelial ovarian cancer (EOC) consists of cytoreductive surgery followed by chemotherapy, preferably including paclitaxel combined with cisplatin or carboplatin (Serkies et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Oridonin Suppresses Proliferation of Human Ovarian Cancer Cells via Blockage of mTOR Signaling

Xiao¹,

Chen²,

Qin³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Oridonin, an ent-kaurane diterpenoid compound isolated from the traditional Chinese herb Rabdosia rubescens, has shown various pharmacological and physiological effects such as anti-tumor, anti-bacterial, and anti-inflammatory properties. However, the effect of oridonin on human ovarian cancer cell lines has not been determined. In this study, we demonstrated that oridonin inhibited ovarian cancer cell proliferation, migration and invasion in a dose-dependent manner. Furthermore, we showed oridonin inhibited tumor growth of ovarian cancer cells (SKOV3) in vivo. We then assessed mechanisms and found that oridonin specifically abrogated the phosphorylation/activation of mTOR signaling. In summary, our results indicate that oridonin is a potential inhibitor of ovarian cancer by blocking the mTOR signaling pathway. Keywords

show abstract

Section: Introductionmentioning

confidence: 99%

Oridonin Suppresses Proliferation of Human Ovarian Cancer Cells via Blockage of mTOR Signaling

Xiao¹,

Chen²,

Qin³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Obtaining access to appropriate care services through delivery systems that are complementary and not duplicative [66] is a primary area of improvement. From this point of view, the establishment of coordination schemes between specialists and primary care physicians, which includes formalization of the transfer of care [53,67,68], is considered insufficient to substantially improve patient management [66].…”

Section: Discussionmentioning

confidence: 99%

“…From this point of view, the establishment of coordination schemes between specialists and primary care physicians, which includes formalization of the transfer of care [53,67,68], is considered insufficient to substantially improve patient management [66]. The coordination strategy should extend to a larger number of health services.…”

Section: Discussionmentioning

confidence: 99%

Should breast cancer survivors be excluded from, or invited to, organised mammography screening programmes?

Bucchi

2011

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundThe prevalence of breast cancer in developed countries has steadily risen over recent decades. Immediate and long-term health needs of patients, including preventive care and screening services, are receiving increasing attention. A question still unresolved is whether breast cancer survivors should receive mammographic surveillance in the clinical or screening setting and, thus, whether they should be excluded from, or invited to, organised mammography screening programmes. The objective of this article is to discuss the many contradictory aspects of this matter.DiscussionProblems with mammographic surveillance of breast cancer survivors include: weak evidence of a reduction in mortality; lack of evidence in favour of one setting or the other; lack of evidence-based guidelines for the frequency and duration of surveillance; disproportionate emphasis placed on the first few years post-treatment, probably dictated by surgical and oncological priorities; a variety of screening policies, as these women are permanently or temporarily or partially excluded from many - but not all - organised screening programmes worldwide; an even greater disparity in follow-up protocols used in the clinical setting; a paucity of data on compliance to mammographic surveillance in both settings; and a difficulty in coordinating the roles of health care providers. In the future, the use of mammography in breast cancer survivors will be influenced by the inclusion of women aged > 69 years in organised screening programmes and the implementation of multidisciplinary breast units, and will probably be investigated by research activities on individual risk assessment and risk-tailored screening. In the interim, current problems can be partially alleviated with some technical solutions in screening data recording, patient flows, and care coordination.SummaryMammographic surveillance of breast cancer survivors is situated at the crossroads of numerous different specialist areas of breast cancer control and management. The solutions for current problems probably lie in some important modifications in the conventional screening procedure that are underway or under study. These developments appear to be directed towards a partial modification of the screening rationale, with an adaptation to meet the diversified breast care needs of women. The complexity of the matter constitutes a call to action for several entities to eliminate the barriers to effective research in this field.

show abstract

“…Because of earlier detection, improved diagnostic methods, more effective treatment, improved clinical follow-up after treatment, and an aging population, the proportion of long-term survivors is rising [2]. Consequently, surveillance and monitoring of cancer survivors has become a critical issue, not only for disease control, but also for cancer treatment and treatment-related health problems [3].…”

Section: Introductionmentioning

confidence: 99%

Estrogen decrease coronary artery disease risk in patients with cervical cancer after treatment

Sun

Liang

Chang

et al. 2012

Gynecologic Oncology

View full text Add to dashboard Cite

Introduction: Charting the landscape of cancer survivors' health‐related outcomes and care

Cited by 20 publications

References 79 publications

Oridonin Suppresses Proliferation of Human Ovarian Cancer Cells via Blockage of mTOR Signaling

Oridonin Suppresses Proliferation of Human Ovarian Cancer Cells via Blockage of mTOR Signaling

Should breast cancer survivors be excluded from, or invited to, organised mammography screening programmes?

Estrogen decrease coronary artery disease risk in patients with cervical cancer after treatment

Contact Info

Product

Resources

About